Unlocking the Therapeutic Potential of Neuroplastogens

Neuroplastogens are  the Next Big Therapeutic Opportunity

Compelling preclinical evidence of enhanced neuroplasticity and cellular resilience support development across a diverse range of indications - from neuropsychiatry to ophthalmology.

Opportunity is an order of magnitude larger than first-generation psychedelic drug candidates because these therapies can be secured, scaled, and rapidly developed through human  proof-of- concept trials.

Negev Labs Drives Value Creation

A Disciplined and Efficient Approach to Company Building

Source, validate and secure valuable IP

Build disease-focused biopharma companies

Rapidly advance to human proof-of-concept trial

Maximize returns via strategic exits

Phase 1b

Our lead candidate starts clinical 
trials in Q3 2024 in patients

more projects

in pre-clinical development
and in discovery

Management Team

Ken Belotsky

CEO, Co-Founder

Partner at Negev Capital since 2021. 
15 years managing startups. Co-founder of Bright Box acquired by Zurich Insurance in 2018. Co-founder of BrightConsult acquired by Incadea in 2011.

Kostia Adamsky

COO, Co-Founder

Principal at Negev Capital . VP Ops at Levco Pharmaceuticals Ltd, CEO & VP Ops at Regenera Pharma LTD., Director and co-CEO at Targia Pharmaceuticals. PhD in cell biology from Weizmann Institute.

Heresh Rezavandi

Chief Strategy & Partnering Officer

14+ years' experience in life science R&D, portfolio, search and evaluation, BD&L, marketing, strategy in global roles at UCB, Bayer, Roche and Angelini. PhD in Biochemistry.

Shlomi Raz

CBO

President & CBO of Beckley Psytech and Founder & CEO of Eleusis Therapeutics. Managing Director at Goldman Sachs. MA from NYU and BS from Georgetown University.

Bernard Lerer, MD, PhD

Science Partner

Professor of Psychiatry at Hadassah-Hebrew University Medical Center and the founder at Hadassah BrainLabs Institute.

C. Anthony Altar

Head of Scientific Advisory Board

40+ years' experience in biotech & psychiatric drug discovery, leader at Genentech, Regeneron, and Otsuka. President & COO at Splice Therapeutics.

Contact us

Thank you for getting in touch!

We appreciate you contacting us. One of our colleagues will get back in touch with you soon!

Have a great day!

Oops! Something went wrong while submitting the form.